Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Konstantin K. Laktionov"'
Autor:
Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valeriy V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Alexander E. Kuzminov, Evgeny V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergey V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Ksenia A. Sarantseva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tyurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Marina V. Chernykh, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Marina M. Khulamkhanova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 269-304 (2022)
Externí odkaz:
https://doaj.org/article/a2caace9aacc43548d9d996d4c2021f2
Autor:
Anastasiya A. Glibka, Natalya V. Mazurina, Ksenia A. Sarantseva, Galina Y. Kharkevich, Konstantin K. Laktionov, Ekaterina A. Troshina, Galina A. Mel`nichenko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 3, Pp 187-195 (2022)
In the recent years, immune checkpoint inhibitors (ICPI) have been widely used for treatment of many malignant neoplasms. In the Russian Federation, several ICPIs have been approved and actively used, namely anti-CTLA-4 monoclonal antibody (ipilimuma
Externí odkaz:
https://doaj.org/article/a54d9493e401479b823636e56ab67995
Autor:
Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valerii V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Aleksandr E. Kuz’minov, Evgenii V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergei V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tiurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Galina A. Tkachenko, Marina M. Khulamkhanova
Publikováno v:
Современная онкология, Vol 23, Iss 3, Pp 369-402 (2021)
Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are
Externí odkaz:
https://doaj.org/article/a0745ce3a3d34da8b1d40865cb268cd1
Publikováno v:
Современная онкология, Vol 23, Iss 3, Pp 428-435 (2021)
Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 a
Externí odkaz:
https://doaj.org/article/a92e51c914374d90b0dcf921ac158329
Publikováno v:
Современная онкология, Vol 23, Iss 3, Pp 425-427 (2021)
The possibilities of treatment of patients with metastatic non-small cell lung cancer have significantly expanded in the recent years. Several combined regimens of chemoimmunotherapy are currently being proposed as the first line, some patients with
Externí odkaz:
https://doaj.org/article/445a66ac50844b09a5bc2e205b4eef57
Autor:
Tatiana N. Borisova, Sergey I. Tkachev, Stanislav M. Ivanov, Sevil B. Alieva, Oxana P. Trofimova, Valeria V. Glebovskaya, Valeriy V. Breder, Konstantin K. Laktionov, Dimitr T. Marinov, Amir G. Abdullaev
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 109-114 (2021)
Pleural mesothelioma (PM) remains a disease with a poor prognosis, despite the use of the newest achievements of multimodal treatment. Radiation therapy for PM is traditionally used in some directions: in radical treatment as a part of a three-modal
Externí odkaz:
https://doaj.org/article/bbe8cd21fc944768923166d11821ad90
Autor:
Konstantin K. Laktionov, Aleksei M. Kazakov, Marat G. Gordiev, Pavel V. Kononets, Bakhrom B. Akhmedov, Julia N. Maevskaia
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 104-107 (2020)
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide range of possible targeted activating mutations. In this regard, a lot of attention is paid to such treatment of patients with NSCLC as adjuvant targeted therapy afte
Externí odkaz:
https://doaj.org/article/1b1bd4636d484295a570f34b0f6e7870
Autor:
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lun Huang, Agnieszka Cseh, Keunchil Park, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Externí odkaz:
https://doaj.org/article/9f20422dd14b455088226a15dd90831a
Autor:
Gilberto de Castro, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S.K. Mok, Byoung Chul Cho
Publikováno v:
Journal of Clinical Oncology. 41:1986-1991
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348befae3eed5619ebf96185ef38fcab
https://doi.org/10.1200/jco.21.02885
https://doi.org/10.1200/jco.21.02885
Autor:
Elena Yu. Antonova, Ekaterina A Moroz, Daniil V. Podlyzny, Nikolai E. Kudashkin, Aleksandr Yu. Volkov, Irina A. Dzhanyan, Konstantin K. Laktionov, Valery V. Breder
Publikováno v:
Russian Journal of Oncology. 26:13-22
BACKGROUND: Fibrolamellar liver carcinoma is a rare subtype of liver cancer with an unexplored etiology. There is no information about the choice of classification for fibrolamellar liver carcinoma (FLC) in the world literature, and data on the progn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19888b4cc8081074aa1c22715fe4c032
https://doi.org/10.17816/1028-9984-2021-26-1-13-22
https://doi.org/10.17816/1028-9984-2021-26-1-13-22